This meeting has now passed.


This symposium will combine short presentations with audience/faculty discussion to highlight the latest evidence regarding current and future markers of disease prognosis, markers of responsiveness to therapy, and non-invasive markers of response. Using the theme "what we know and what we don't" the presentations will highlight current knowledge and call for additional research. Finally, the discussion sessions will consider how management should be adjusted to improve patient outcomes, including if and how "accelerated step-up" therapy to biologics can play a role.


As the pathogenesis and natural history of Crohn's disease becomes better understood there is considerable interest in the emerging ability to stratify patients with CD to better reflect the different phenotypes. Notably, as disease progresses to a less inflammatory and more structuring disease, current therapies may be less effective. Prognostic factors which may have clinical application now, or in the near future, include serologic, clinical, and genetic markers, and there is now potential to use some of these to better individualize therapy including, for patients with more severe disease, a more aggressive management strategy which might include "step-in" or an "accelerated step-up" approach. For these patients earlier initiation of biologic therapy may improve long-term outcomes.


This activity has been designed to meet the educational needs of physicians, registered nurses, and other healthcare professionals involved in the management of patients with inflammatory bowel disease.